SEC Filing Summary for Edward Pershing

On September 18, 2026, Edward Pershing, CEO, Director, and 10% owner of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), reported a transaction involving an 8% unsecured convertible promissory note. The note, originally issued under the Issuer's 2025 Financing, automatically converted into 13,216 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. This conversion occurred twelve months after the note's issue date. The Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier. Following this transaction, Pershing owns 2,962,709 shares of Series D-1 Convertible Preferred Stock. The filing is a Form 4, indicating a change in beneficial ownership.